Bevacizumab was considered because of positive VEGF immunostaining in the tumor and in view of previous successful use in a patient with a pituitary carcinoma that resulted in prolonged (>8 years) control of tumor growth and survival [(16) and personal communication with Dr Luis Syro, Medellin, Colombia]. This evidence concerns the gene VEGFA and pituitary adenocarcinoma.